Erasca, Inc.

87 articles about Erasca, Inc.

• Erasca Announces $45 Million Oversubscribed Private Placement Financing

  3/28/2024

  Erasca, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share.

• Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

  3/27/2024

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

• Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

  2/14/2024

  Erasca, Inc. today announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis (NYSE: NVS) for the MEK inhibitor trametinib (MEKINIST®).

• Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

  2/1/2024

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York. 

• Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  1/3/2024

  Erasca, Inc. today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA.

• Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

  12/11/2023

  Erasca, Inc. (Nasdaq: ERAS) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm).

• Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

  11/28/2023

  Erasca, Inc. announced program updates for pan-RAF inhibitor naporafenib and central nervous system -penetrant EGFR inhibitor ERAS-801, as well as a strategic program prioritization that extends its projected cash runway from H2 2025 to H1 2026.

• Erasca Reports Third Quarter 2023 Financial Results and Business Updates

  11/9/2023

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended September 30, 2023, and provided business updates.

• Erasca to Present at Upcoming Investor Conferences in November 2023

  11/8/2023

  Erasca, Inc. announced that management will participate in the following investor conferences in November 2023.

• Erasca to Present at the Cantor Global Healthcare Conference

  9/19/2023

  Erasca, Inc. today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York.

• Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

  9/5/2023

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference.

• Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

  8/29/2023

  Erasca, Inc. (Nasdaq: ERAS) today announced dosing of the first patient in the SEACRAFT-1 Phase 1b trial evaluating pan-RAF inhibitor naporafenib in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.

• Erasca Reports Second Quarter 2023 Financial Results and Business Updates

  8/10/2023

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended June 30, 2023, and provided business updates.

• Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

  6/22/2023

  Erasca, Inc. (Nasdaq: ERAS) today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ERAS-801 for the treatment of malignant glioma, which includes glioblastoma (GBM).

• Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

  6/5/2023

  Erasca, Inc. (Nasdaq: ERAS) today announced promising preliminary Phase 1b data for ERK inhibitor ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC) and provided a portfolio update.

• Erasca to Present at Upcoming June 2023 Investor Conferences

  6/1/2023

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced that management will present at the investor conferences listed below.

• Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

  5/31/2023

  Erasca, Inc. announced it will host a virtual investor event on Erasca pipeline updates on Monday, June 5, 2023, at 4:30 PM ET.

• Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

  5/25/2023

  Erasca, Inc. announced preliminary Phase 1b data for ERAS-007 combinations in patients with GI malignancies from two poster presentations at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

• Erasca Further Strengthens Business Leadership with Two Key Promotions

  5/16/2023

  Erasca, Inc. announced that David Chacko, M.D., previously chief financial officer of Erasca, has been promoted to the dual position of CFO and chief business officer, and Nik Chetwyn, Ph.D., previously senior vice president of operations of Erasca, has been promoted to chief operating officer, with each promotion being effective as of May 15, 2023.

• Erasca Reports First Quarter 2023 Financial Results and Business Updates

  5/15/2023

  Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2023, and provided business updates.